Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: A clinical randomized study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Challenges and obstacles in the transition process through the eyes of the gastroenterologist

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Paediatric hepatitis B and hepatitis C virus infections: an observational study of a Danish cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association between vancomycin-resistant Enterococcus faecium colonization and subsequent infection: a retrospective WGS study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Equine pegiviruses cause persistent infection of bone marrow and are not associated with hepatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Objective New potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of adverse events (AEs) across different DAA regimens is limited. We aimed to evaluate differences in AEs and treatment efficacy in patients with chronic hepatitis C (CHC), genotype (GT) 1 or 3, randomized to two different treatment arms, correspondingly. Patients and methods We randomly assigned 96 patients in a 1: 1 ratio, to treatment for 12 weeks with either paritaprevir/ombitasvir/ritonavir/dasabuvir/ribavirin (RBV) or ledipasvir/sofosbuvir (SOF)/RBV if infected with GT1 (72 patients) or to daclatasvir/SOF/RBV for 12 weeks or SOF/RBV for 24 weeks, if infected with GT3 (24 patients). Data on AEs were collected throughout the entire study period. Results A total of 70 (97%) patients with CHC with GT1 and 20 (83%) patients with GT3 achieved cure. The GT3 treatment arm was prematurely terminated, owing to change in national treatment guidelines. Thus, only AEs for GT1 patients are described. AEs occurred in 70 (97%) GT1 patients, and most common AEs were anemia (n=56/78%), fatigue (n=53/74%), and headache (n=33/46%). No difference was observed in relation to treatment group (P=1.0), anemia (P=1.0), or liver cirrhosis (P=0.53). In seven (11%) patients, AEs assessed by the investigator to be possibly related to the DAA regimen were still present 12 weeks after treatment. Conclusions We found no difference in AEs possibly related to the DAA regimen in patients with CHC, but surprisingly, AEs possibly related to the DAA regimen persisted in a significant number of patients after treatment. This finding can be of importance for clinicians in relation to patient information concerning AEs possibly related to DAA treatment.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Gastroenterology and Hepatology
Vol/bind30
Udgave nummer10
Sider (fra-til)1177-1186
Antal sider10
ISSN0954-691X
DOI
StatusUdgivet - 1 okt. 2018

ID: 55443633